INLYTA (U.S. Pharmaceuticals)


Welcome to the PulseAid listing for the INLYTA drug offered from U.S. Pharmaceuticals. This Kinase Inhibitor [EPC],Receptor Tyrosine Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: U.S. Pharmaceuticals
NON-PROPRIETARY NAME: axitinib
SUBSTANCE NAME: AXITINIB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Kinase Inhibitor [EPC],Receptor Tyrosine Kinase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2012-01-27
END MARKETING DATE: 0000-00-00


INLYTA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionINLYTA from U.S. Pharmaceuticals
LABELER NAME: U.S. Pharmaceuticals
DEA SCHEDULE:
ACTIVE STRENGTH: 1(mg/1)
START MARKETING DATE: 2012-01-27
END MARKETING DATE: 0000-00-00
PRODUCT ID: 63539-026_52b7daa9-f0b6-493f-91c3-c204842c43e0
PRODUCT NDC: 63539-026
APPLICATION NUMBER: NDA202324

Other AXITINIB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Pfizer Laboratories Div Pfizer IncINLYTA
U.S. PharmaceuticalsINLYTA